SG11202002116YA - Methods of preventing methionine oxidation in immunoconjugates - Google Patents
Methods of preventing methionine oxidation in immunoconjugatesInfo
- Publication number
- SG11202002116YA SG11202002116YA SG11202002116YA SG11202002116YA SG11202002116YA SG 11202002116Y A SG11202002116Y A SG 11202002116YA SG 11202002116Y A SG11202002116Y A SG 11202002116YA SG 11202002116Y A SG11202002116Y A SG 11202002116YA SG 11202002116Y A SG11202002116Y A SG 11202002116YA
- Authority
- SG
- Singapore
- Prior art keywords
- immunoconjugates
- methods
- methionine oxidation
- preventing
- preventing methionine
- Prior art date
Links
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 229930182817 methionine Natural products 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000003647 oxidation Effects 0.000 title 1
- 238000007254 oxidation reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562049P | 2017-09-22 | 2017-09-22 | |
| US201762573322P | 2017-10-17 | 2017-10-17 | |
| US201862712584P | 2018-07-31 | 2018-07-31 | |
| PCT/US2018/052197 WO2019060707A1 (en) | 2017-09-22 | 2018-09-21 | METHODS FOR PREVENTING OXIDATION OF METHIONINE IN IMMUNOCONJUGATES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002116YA true SG11202002116YA (en) | 2020-04-29 |
Family
ID=63794732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002116YA SG11202002116YA (en) | 2017-09-22 | 2018-09-21 | Methods of preventing methionine oxidation in immunoconjugates |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190111147A1 (zh) |
| EP (2) | EP3684412B1 (zh) |
| JP (2) | JP7203834B2 (zh) |
| KR (1) | KR20200070254A (zh) |
| CN (2) | CN117065043A (zh) |
| AU (1) | AU2018335780A1 (zh) |
| CA (1) | CA3075896A1 (zh) |
| IL (2) | IL273384B2 (zh) |
| MA (1) | MA50266A (zh) |
| SG (1) | SG11202002116YA (zh) |
| TW (1) | TW201919711A (zh) |
| WO (1) | WO2019060707A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3313884B9 (en) * | 2015-06-29 | 2021-05-19 | ImmunoGen, Inc. | Anti-cd123 antibodies and conjugates and derivatives thereof |
| CA3137454A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Therapeutic combinations comprising anti-cd123 immunoconjugates |
| CN114401744A (zh) * | 2019-06-26 | 2022-04-26 | 纪念斯隆凯特琳癌症中心 | 用于治疗癌症的抗cd33抗体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU2003285878B2 (en) | 2002-11-07 | 2011-04-28 | Immunogen, Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
| US20100030670A1 (en) * | 2008-08-04 | 2010-02-04 | Mastercard International, Inc. | Method of monitoring different debit card transactions associated with a single funding source |
| KR20110076918A (ko) | 2008-09-10 | 2011-07-06 | 제넨테크, 인크. | 단백질의 산화성 분해를 방지하기 위한 조성물 및 방법 |
| JP2010241718A (ja) | 2009-04-03 | 2010-10-28 | Kyowa Hakko Kirin Co Ltd | 安定な抗体の水溶液製剤 |
| CN105073136A (zh) | 2013-03-15 | 2015-11-18 | 葛兰素史克知识产权第二有限公司 | 低浓度抗体制剂 |
| JP6517468B2 (ja) * | 2014-01-10 | 2019-05-22 | 日本電気株式会社 | 情報処理システム、情報処理装置、監視装置、監視方法、及び、プログラム |
| EP3313884B9 (en) | 2015-06-29 | 2021-05-19 | ImmunoGen, Inc. | Anti-cd123 antibodies and conjugates and derivatives thereof |
| WO2017091745A1 (en) | 2015-11-25 | 2017-06-01 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
-
2018
- 2018-09-21 MA MA050266A patent/MA50266A/fr unknown
- 2018-09-21 IL IL273384A patent/IL273384B2/en unknown
- 2018-09-21 JP JP2020516662A patent/JP7203834B2/ja active Active
- 2018-09-21 US US16/138,158 patent/US20190111147A1/en not_active Abandoned
- 2018-09-21 CA CA3075896A patent/CA3075896A1/en active Pending
- 2018-09-21 EP EP18783303.3A patent/EP3684412B1/en active Active
- 2018-09-21 WO PCT/US2018/052197 patent/WO2019060707A1/en unknown
- 2018-09-21 CN CN202310589494.0A patent/CN117065043A/zh active Pending
- 2018-09-21 CN CN201880075572.2A patent/CN111372610B/zh active Active
- 2018-09-21 TW TW107133293A patent/TW201919711A/zh unknown
- 2018-09-21 KR KR1020207011137A patent/KR20200070254A/ko not_active Application Discontinuation
- 2018-09-21 SG SG11202002116YA patent/SG11202002116YA/en unknown
- 2018-09-21 EP EP24156669.4A patent/EP4374850A2/en active Pending
- 2018-09-21 AU AU2018335780A patent/AU2018335780A1/en active Pending
-
2021
- 2021-12-13 US US17/549,327 patent/US20220202947A1/en not_active Abandoned
-
2022
- 2022-12-27 JP JP2022209534A patent/JP2023036874A/ja active Pending
-
2023
- 2023-07-18 IL IL304551A patent/IL304551A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3075896A1 (en) | 2019-03-28 |
| IL273384B2 (en) | 2023-12-01 |
| CN111372610B (zh) | 2023-05-30 |
| RU2020113280A3 (zh) | 2022-04-11 |
| RU2020113280A (ru) | 2021-10-25 |
| CN111372610A (zh) | 2020-07-03 |
| EP3684412B1 (en) | 2024-02-14 |
| CN117065043A (zh) | 2023-11-17 |
| JP2023036874A (ja) | 2023-03-14 |
| JP7203834B2 (ja) | 2023-01-13 |
| IL273384B1 (en) | 2023-08-01 |
| MA50266A (fr) | 2020-07-29 |
| US20220202947A1 (en) | 2022-06-30 |
| JP2020534326A (ja) | 2020-11-26 |
| KR20200070254A (ko) | 2020-06-17 |
| EP3684412A1 (en) | 2020-07-29 |
| EP4374850A2 (en) | 2024-05-29 |
| WO2019060707A1 (en) | 2019-03-28 |
| US20190111147A1 (en) | 2019-04-18 |
| TW201919711A (zh) | 2019-06-01 |
| IL273384A (en) | 2020-05-31 |
| AU2018335780A1 (en) | 2020-03-26 |
| IL304551A (en) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261428A (en) | Antibody-drug conjugates based on eribulin and methods of use | |
| HK1250646A1 (zh) | 納米粒子免疫偶聯物 | |
| IL250461A0 (en) | Anti-cll-1 antibodies and immunoconjugates | |
| AU201710083S (en) | Bowl and Covered Bowl | |
| ZA201805805B (en) | Formulations and methods | |
| HK1255141A1 (zh) | 包含抗folr1免疫綴合物的治療組合 | |
| GB201507908D0 (en) | IL2 and TNF immunoconjugates | |
| EP3334429C0 (en) | HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR | |
| HK1255483A1 (zh) | 抗體和免疫結合物 | |
| IL248281A0 (en) | The composition for oral care containing silica and zinc citrate | |
| IL304551A (en) | Methods to prevent methionine oxidation in immune conjugates | |
| GB201421163D0 (en) | Formulations of metal complexes | |
| HK1254987A1 (zh) | 水性化妝品組合物 | |
| HK1258409A1 (zh) | 抗cd22抗體-美登木素綴合物及其使用方法 | |
| GB201519200D0 (en) | Skin care composition and method thereof | |
| HK1256368A1 (zh) | 加利車黴素-抗體-藥物綴合物和使用方法 | |
| IL266721A (en) | Anti-gp73 antibodies and immunoconjugates | |
| HK1259451A1 (zh) | 護膚組合物及其方法 | |
| EP3256098C0 (en) | DENTAL COMPOSITION AND USE | |
| GB201611406D0 (en) | Skin care composition and method thereof | |
| GB201515194D0 (en) | Nappy and insert therefor | |
| ZA201904626B (en) | Cancer treatment method and composition | |
| GB201713009D0 (en) | Methods for reducing oxidation | |
| GB201608716D0 (en) | Bioorthogonal compounds and methods | |
| GB201611362D0 (en) | Skin care composition and method thereof |